ReviewExtracellular vesicles and circulating nucleic acids2026
A multidimensional landscape of extracellular vesicle-mediated tumor drug resistance: mechanisms, biomarkers, engineered drug delivery, and clinical translation.
Review in Extracellular vesicles and circulating nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor drug resistance is a major clinical challenge that limits the efficacy of chemotherapy, targeted therapy, and immunotherapy, thereby contributing to tumor recurrence, metastasis, and reduced overall patient survival rates. Recent studies reveal that extracellular vesicles (EVs) in the tumor microenvironment act as key mediators of intercellular communication. They play a central role in mediating tumor cell resistance by transporting functional cargo, including RNA, proteins, and lipids. This review outlines the mechanisms of EV-mediated tumor resistance, including key processes such as drug efflux, evasion of apoptosis, maintenance of epithelial-mesenchymal transition and cancer stem cell phenotypes, remodeling of the immune microenvironment, metabolic reprogramming, and expansion of resistant cell populations. It also discusses the use of EVs as biomarkers of resistance and their associated detection technologies. Furthermore, this paper highlights therapeutic strategies for reversing drug resistance through engineered EVs, including the delivery of small molecules, nucleic acid therapeutics, and key bioactive components. It also reviews current preclinical studies and progress toward clinical translation of EV-based resistance reversal strategies. This review aims to elucidate the role and translational potential of EVs in tumor drug resistance through a systematic approach that integrates mechanism exploration, biomarker identification, engineered drug delivery, and clinical translation. It provides a comprehensive reference to facilitate further advances in this field, from basic research to clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.